Allegra Asthma Claim Would Be Key Defense Vs. Forced OTC Switch – Aventis
This article was originally published in The Tan Sheet
Executive Summary
Aventis' Allegra experimental asthma indication would be the best defense against a forced OTC switch of the antihistamine, Chief Operating Officer Richard Markham told analysts during Aventis' R&D day in London June 18